Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 20/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 16/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10233877 | 0.85 | KCNJ1 (1.00) | KCNJ1KCNH2 | |
| SCHEMBL18043559 | 0.84 | KCNJ1 (0.63) | KCNJ1KCNH2SLC6A4 | |
| SCHEMBL16686868 | 0.80 | KCNJ1 (0.57) | KCNJ1KCNH2SLC6A4 | |
| SCHEMBL286379 | 0.79 | KCNJ1 (0.82) | KCNJ1KCNH2SLC6A4 | |
| SCHEMBL4549624 | 0.79 | KCNJ1 (0.79) | KCNJ1KCNH2SLC6A4 | |
| Hydrochloric Acid SCHEMBL298344 | 0.78 | KCNJ1 (0.80) | KCNJ1KCNH2SLC6A4 | |
| SCHEMBL20686505 | 0.77 | KCNJ1 (0.53) | KCNJ1KCNH2SLC6A4 | |
| SCHEMBL14785890 | 0.77 | KCNH2 (0.76) | KCNJ1KCNH2SLC6A4 | |
| SCHEMBL16685085 | 0.77 | KCNJ1 (0.66) | KCNJ1KCNH2 | |
| SCHEMBL16684940 | 0.76 | KCNJ1 (0.62) | KCNJ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3063142-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2019-01-30 | — | — | EP | disclosed |
| EP-3063142-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2019-01-30 | — | — | EP | disclosed |
| US-9951052-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951052-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951052-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160257670-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME CORP. (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257670-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME CORP. (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257670-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME CORP. (US) | 2016-09-08 | — | — | US | disclosed |
| EP-3063142-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2016-09-07 | — | — | EP | disclosed |
| WO-2015065866-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2015-05-07 | — | — | WO | disclosed |
| WO-2015065866-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257670-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885KCNH2 22/4885SLC6A4 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.